Kobayashi Pandya Takesue Mikamo Deane

199 WEDNESDAY SCIENTIFIC SESSIONS Final Program F-2026 Comparative Pharmacokinetics of Novel Inhibitors of DNA GyraseTopoisomerase IV V. Ong, V. Brown-Driver, C. L. Hall, G. W. Hough, K. Nelson; Trius Therapeutics, Inc., San Diego, CA. F-2027 Use of Microdosing and Accelerator Mass Spectrometry to Evaluate the Pharmacokinetics of a Novel GyrBParE Inhibitor

M. A. Malfatti

1 , V. Lao 1 , K. W. Turteltaub 1 , C. L. Hall 2 , V. S. Ong 2 ; 1 Lawrence Livermore Natl. Lab., Livermore, CA, 2 Trius Therapeutics, Inc., San Diego, CA. F-2028 Activity of Novel, Dual Targeting Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV in Murine Infection Models

T. M. Murphy

1 , M. A. Blair 1 , S. Little 1 , A. M. Slee 1 , V. Brown-Driver 2 , K. J. Shaw 2 ; 1 ViviSource Lab., Inc, Waltham, MA, 2 Trius Therapeutics, Inc., San Diego, CA. F-2029 In Vitro Activity and Pharmacodynamic PD Evaluation of Dual Targeting Inhibitors of Bacterial DNA Gyrase and Topoi- somerase IV DTIs against Extracellular and Intracellular Forms of Ciprofloxacin-Susceptible CIPS and Ciprofloxacin-Resistant CIPR Pseudomonas aeruginosa PA and Staphylococcus aureus SA J. M. Buyck 1 , S. Lemaire 1 , D. Pierard 2 , F. Van Bambeke 1 , P. M. Tulkens 1 ; 1 Univ. Catholique de Louvain, Bruxelles, Belgium, 2 Vrije Univ. Brussel, Bruxelles, Belgium. ------------------------------------------------------------------------ 248 F Poster Session Quinolones and Beyond Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: F-2030 Ev-035: Novel 2-Pyridone Based Topoisomerase Inhibitors with Broad-Spectrum Activity against MDR Pathogens, Including Quinolone Resistance

J. Heim, P. Roussel, D. Milligan, S. Goldman; Evolva, Reinach, Switzerland. F-2031

Ev-035: Synthesis and In Vitro Antibacterial Activity of a New Series of 2-Pyridone Based Topoisomerase Inhibitors

P. Roussel, G. Liu, D. Milligan, S. Goldman, J. Heim; Evolva SA, Reinach, Switzerland.

F-2032 Ev-035: In Vitro ADMET, Mouse PK and Efficacy in Murine Infection Models of a New Orally Available Class of Antibiotics

G. Salerno, J. Heim, S. Goldman, D. Milligan, P. Roussel; Evolva, Reinach, Switzerland.

F-2033 EV-035: Potent Antibiotic Series against Biothreat Agent Burkholderia pseudomallei

S. Goldman

1 , G. Salerno 1 , D. Milligan 1 , P. Roussel 1 , N. Marlenee 2 , R. Bowen 2 , N. Podnecky 2 , H. P. Schweizer 2 , J. Heim 1 ; 1 Evolva, Reinach, Switzerland, 2 Colorado State Univ., Fort Collins, CO. F-2034 Activity and Pharmacokinetics of Clinafloxacin for Bovine and Swine Respiratory Disease M. T. Sweeney, R. Quesnell, R. Tiwari, M. LeMay, C. Benner, J. Watts; Pfizer, Kalamazoo, MI. F-2035 DS-8587, a New Generation of Broad Spectrum Quinolone: Pharmacodynamic and Therapeutic Efficacy in Animal Infection Models

Y. Kurosaka, S. Uoyama, C. Ishii, K. Hoshino; Daiichi Sankyo Co., Ltd., Tokyo, Japan.

F-2036 DS-8587, a New Generation of Broad Spectrum Quinolone: In Vitro Antibacterial Activities against Chinese Clinical Isolates

D. Zhu

1 , Y. Kurosaka 2 , K. Hoshino 2 ; 1 Huashan Hosp., Fudan Univ., Shanghai, China, 2 Daiichi Sankyo, Co., Ltd., Tokyo, Japan. F-2037 DS-8587, a New Generation of Broad Spectrum Quinolone: Antibacterial Spectrum and its In Vitro Activities against Clinical Isolates in Japan

M. Chiba, K. Fujikawa, R. Okumura, K. Yuichi, K. Hoshino; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.

F-2038 DS-8587, a New Generation of Broad Spectrum Quinolone: Mode of Action and Frequency of Resistant Mutants of Major Pathogens

R. Okumura, Y. Onodera, M. Chiba, K. Fujikawa, K. Hoshino; Daiichi Sankyo, Co. Ltd., Tokyo, Japan.

F-2039 DS-8587, a New Generation of Broad Spectrum Quinolone: In Vitro Antibacterial Activities against

A. baumannii

S. Higuchi

1,2 , Y. Onodera 1 , M. Chiba 1 , K. Hoshino 1 , N. Gotoh 2 ; 1 Daiichi Sankyo, Co. Ltd., Tokyo, Japan, 2 Kyoto Pharmaceutical Univ., Kyoto, Japan. F-2040 DS-8587, a New Generation of Broad Spectrum Quinolone: In Vitro Antibacterial Activity against Japanese Clinical Isolates of ESBL Producing Escherichia coli

Y. Ishii

1 , M. Chiba 2 , K. Hoshino 2 , K. Tateda 1 ; 1 Toho Univ. Sch. of Med., Tokyo, Japan, 2 Daiichi Sankyo, Co., Ltd., Tokyo, Japan. F-2041 DS-8587, a New Generation of Broad Spectrum Quinolone: Nonclinical and Clinical Pharmacokinetic Profiles

N. Kobayashi

1 , T. Shimizu 1 , K. Toyama 1 , E. Kamiyama 1 , E. Suzuki 1 , T. Abiko 1 , H. Fukase 2 , T. Tokui 1 , T. Izumi 1 ; 1 Daiichi Sankyo, Co. Ltd., Tokyo, Japan, 2 CPC Clinical Trial Hosp., Kagoshima, Japan. F-2042 DS-8587, a New Generation of Broad Spectrum Quinolone: Safety Profile in Preclinical Studies H. Miida, Y. Tsuchiya, S. Itoh, K. Noritake, T. Ishizaka, W. Takasaki; Daiichi Sankyo, Co. Ltd., Shizuoka, Japan. F-2043 DS-8587, a New Generation of Broad Spectrum Quinolone: Pharmacodynamics and In Vivo Efficacy against Acinetobactor baumannii

M. Pandya

1 , T. K. Barman 1 , E. P. M. Rao 1 , M. Kumar 1 , S. Singhal 1 , D. J. Upadhyay 1 , Y. Kurosaka 2 , S. Uoyama 2 , C. Ishii 2 , K. Hoshino 2 ; 1 Daiichi Sankyo Life Sci. Res. Ctr. Gurgaon, India, 2 Daiichi Sankyo, Co. Ltd., Tokyo, Japan. F-2044 DS-8587, a New Generation of Broad Spectrum Quinolone: In Vitro Antibacterial Activity against Clinical Isolates from Postoperative Intraabdominal Infections IAIs

Y. Takesue

1 , M. Chiba 2 , K. Hoshino 2 ; 1 Hyogo Coll. of Med., Nishinomiya, Japan, 2 Daiichi Sankyo, Co. Ltd., Tokyo, Japan. 200 SCIENTIFIC SESSIONS September 9-12 | F-2045 DS-8587, a New Generation of Broad Spectrum Quinolone: In Vitro Antibacterial Activity against 9 Major Anaerobic Species of Japanese Clinical Isolates

H. Mikamo

1 , Y. Yamagishi 1 , H. Suematsu 1 , H. Sawamura 1 , M. Chiba 2 , R. Okumura 2 , K. Hoshino 2 ; 1 Aichi Med. Univ., Aichi, Japan, 2 Daiichi Sankyo, Co. Ltd., Tokyo, Japan. F-2046 In Vitro Activity of KPI-10 against Clinically Important Gram-Negative Bacteria

J. Deane

1 , A. Simenauer 1 , Y. Ge 2 , P. B. Eckburg 2 , D. Sahm 1 ; 1 Eurofins, Chantilly, VA, 2 Kalidex Pharmaceuticals, Inc., Menlo Park, CA. F-2047 In Vitro Activity of KPI-10 against Clinically Important Gram-Positive Bacteria

J. Deane

1 , A. Simenauer 1 , Y. Ge 2 , P. Eckburg 2 , D. Sahm 1 ; 1 Eurofins, Chan- tilly, VA, 2 Kalidex Pharmaceuticals Inc., Menlo Park, CA. F-2048 Activity of Novel Fluoroquinolone, KPI-10, vs. Multidrug- Resistant Bacteria, Including those with NDM-1 Carbapenemase

D. M. Livermore, M. Warner, S. Mushtaq; Hlth. Protection Agency, Lon- don, United Kingdom.